PL3117828T3 - Sposób namnażania komórek i środek farmaceutyczny do naprawy i regeneracji tkanek - Google Patents

Sposób namnażania komórek i środek farmaceutyczny do naprawy i regeneracji tkanek

Info

Publication number
PL3117828T3
PL3117828T3 PL16182980T PL16182980T PL3117828T3 PL 3117828 T3 PL3117828 T3 PL 3117828T3 PL 16182980 T PL16182980 T PL 16182980T PL 16182980 T PL16182980 T PL 16182980T PL 3117828 T3 PL3117828 T3 PL 3117828T3
Authority
PL
Poland
Prior art keywords
proximation
regeneration
cell
pharmaceutical agent
tissue repair
Prior art date
Application number
PL16182980T
Other languages
English (en)
Inventor
Osamu Honmou
Kiyohiro Houkin
Original Assignee
Sapporo Medical University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP2007235436A external-priority patent/JP2009065854A/ja
Priority claimed from JP2007236499A external-priority patent/JP2009065884A/ja
Priority claimed from JP2007278049A external-priority patent/JP2009107929A/ja
Priority claimed from JP2007278083A external-priority patent/JP2009100719A/ja
Application filed by Sapporo Medical University filed Critical Sapporo Medical University
Publication of PL3117828T3 publication Critical patent/PL3117828T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/12—Chemical aspects of preservation
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/16—Physical preservation processes
    • A01N1/162—Temperature processes, e.g. following predefined temperature changes over time
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0679—Cells of the gastro-intestinal tract
    • C12N5/068—Stem cells; Progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/60—Buffer, e.g. pH regulation, osmotic pressure
    • C12N2500/62—DMSO
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/70—Undefined extracts
    • C12N2500/80—Undefined extracts from animals
    • C12N2500/84—Undefined extracts from animals from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/90—Polysaccharides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/90—Polysaccharides
    • C12N2501/91—Heparin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
PL16182980T 2007-09-11 2008-09-10 Sposób namnażania komórek i środek farmaceutyczny do naprawy i regeneracji tkanek PL3117828T3 (pl)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
JP2007235436A JP2009065854A (ja) 2007-09-11 2007-09-11 細胞増殖方法ならびに組織の修復および再生のための医薬
JP2007236499A JP2009065884A (ja) 2007-09-12 2007-09-12 細胞増殖方法ならびに組織の修復および再生のための医薬
JP2007267211 2007-10-12
JP2007278049A JP2009107929A (ja) 2007-10-12 2007-10-25 損傷部位の修復を幇助する非経口全身投与剤
JP2007278083A JP2009100719A (ja) 2007-10-25 2007-10-25 改善された増殖能を有する細胞およびその評価方法
EP08830989.3A EP2194121B1 (en) 2007-09-11 2008-09-10 Cell growth method and pharmaceutical preparation for tissue repair and regeneration
EP16182980.9A EP3117828B1 (en) 2007-09-11 2008-09-10 Cell proliferation method, and pharmaceutical agent for repair and regeneration of tissue
PCT/JP2008/002503 WO2009034708A1 (ja) 2007-09-11 2008-09-10 細胞増殖方法ならびに組織の修復および再生のための医薬

Publications (1)

Publication Number Publication Date
PL3117828T3 true PL3117828T3 (pl) 2020-05-18

Family

ID=42113874

Family Applications (2)

Application Number Title Priority Date Filing Date
PL08830989T PL2194121T3 (pl) 2007-09-11 2008-09-10 Sposób hodowania komórek i preparat farmaceutyczny do naprawy i regeneracji tkanek
PL16182980T PL3117828T3 (pl) 2007-09-11 2008-09-10 Sposób namnażania komórek i środek farmaceutyczny do naprawy i regeneracji tkanek

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL08830989T PL2194121T3 (pl) 2007-09-11 2008-09-10 Sposób hodowania komórek i preparat farmaceutyczny do naprawy i regeneracji tkanek

Country Status (12)

Country Link
US (3) US9700582B2 (pl)
EP (2) EP2194121B1 (pl)
JP (1) JP4936341B2 (pl)
KR (3) KR102087366B1 (pl)
CN (1) CN101802174B (pl)
AU (1) AU2008298816B2 (pl)
CA (1) CA2699236C (pl)
DK (2) DK2194121T3 (pl)
ES (2) ES2611021T3 (pl)
PL (2) PL2194121T3 (pl)
PT (2) PT2194121T (pl)
WO (1) WO2009034708A1 (pl)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2194121T (pt) * 2007-09-11 2016-12-05 Univ Sapporo Medical Método de proliferação celular e agente farmacêutico para reparação e regeneração de tecidos
PL2602310T3 (pl) * 2010-08-03 2020-07-13 Sapporo Medical University System hodowli komórek szpiku kostnego zawierających surowicę autologiczną, sposób hodowli komórek szpiku kostnego zawierających surowicę autologiczną i sposób wytwarzania kompozycji leczniczej zawierającej jako składnik aktywny hodowane komórki szpiku kostnego zawierające surowicę autologiczną
US10016458B2 (en) 2012-04-16 2018-07-10 Baystate Health, Inc. p53 silenced endothelial progenitor cells for diabetes
EP2953473B1 (en) 2013-02-06 2018-11-28 Nc Medical Research Inc. Method of producing a heterogeneous subpopulation of bone marrow cells suitable for the treatement of neurodegeneration cased by ischemic stroke
WO2015034660A1 (en) * 2013-09-05 2015-03-12 The Regents Of The University Of California Mesenchymal stem cells for oral inflammation treatment
US12171786B2 (en) 2015-10-05 2024-12-24 The Regents Of The University Of California Use of mesenchymal stem cells for the treatment of inflammation
CN105566460B (zh) * 2016-01-19 2018-11-23 南通大学 抑制肿瘤细胞增殖的多肽类似物和对应的编码cDNA及应用
JP6781973B2 (ja) * 2016-01-29 2020-11-11 学校法人東京女子医科大学 腎臓病進行抑制細胞シート組成物、その製造方法、及び、それを用いた腎臓病進行抑制方法
KR20190004307A (ko) 2016-04-28 2019-01-11 훗카이도 코리츠 다이가쿠 호진 삿포르 이카 다이가쿠 시냅스 형성제
CN106153919B (zh) * 2016-06-16 2018-06-29 汕头大学医学院 CD105，esVEGR2和MYC三蛋白联合预测食管鳞癌患者预后试剂盒
WO2018034023A1 (ja) * 2016-08-18 2018-02-22 北海道公立大学法人札幌医科大学 寿命延長剤
WO2018034314A1 (ja) * 2016-08-18 2018-02-22 北海道公立大学法人札幌医科大学 間葉系幹細胞活性化剤
WO2018043596A1 (ja) 2016-08-30 2018-03-08 国立大学法人 新潟大学 細胞製剤および細胞製剤の製造方法
US11542473B2 (en) 2016-10-21 2023-01-03 Amniotics Ab Methods and compositions for generating hematopoietic cells
JP6438527B2 (ja) * 2017-06-01 2018-12-12 Ｎｃメディカルリサーチ株式会社 神経変性の治療のための細胞療法
CN109517789B (zh) * 2017-09-19 2022-05-27 北京大学 Ghrelin活性剂用于诱导干细胞向软骨细胞分化
CA3082368A1 (en) * 2017-11-09 2019-05-16 Sapporo Medical University Medicine for tissue regeneration, and preparation method therefor
CN108535479B (zh) * 2018-04-04 2019-04-19 首都医科大学附属北京地坛医院 sCD163检测试剂在梅毒检测中的应用及包括该试剂的试剂盒
KR102723986B1 (ko) * 2018-04-25 2024-10-31 훗카이도 코리츠 다이가쿠 호진 삿포르 이카 다이가쿠 생체 이식용 세포 시트 및 그 제조 방법
CN110870917B (zh) * 2018-09-03 2022-03-15 上海市第一人民医院 Ews或其上调剂在制备治疗糖尿病及防治糖尿病个体肿瘤发生的药物中的应用
EP3922310A4 (en) 2019-02-07 2022-11-23 Sapporo Medical University PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OF IN-STENT RESTENOSIS
AU2020236160B2 (en) * 2019-03-14 2025-07-24 Nipro Corporation Pharmaceutical composition for treating amyotrophic lateral sclerosis
EP3986358A4 (en) 2019-06-20 2023-06-21 Amniotics AB DEVICE FOR FILTERING FRUIT WATER
EP4234019A3 (en) 2019-10-18 2023-09-13 Amniotics AB Processes and apparatuses for obtaining amniotic mesenchymal stem cells from amniotic fluid and cells derived thereof
CN112899223A (zh) * 2019-12-04 2021-06-04 陕西光子动力航天科技有限公司 宫血干细胞制备方法
JP7663202B2 (ja) * 2019-12-27 2025-04-16 北海道公立大学法人 札幌医科大学 哺乳動物細胞を培養するための血清の製造方法
JP7328729B2 (ja) 2020-03-31 2023-08-17 Ｃｅｌｌ Ｅｘｏｓｏｍｅ Ｔｈｅｒａｐｅｕｔｉｃｓ株式会社 細胞の保存方法
US20230302055A1 (en) * 2020-09-03 2023-09-28 Two Cells Co., Ltd. Composition for treating central nervous system diseases, method for producing composition for treating central nervous system diseases, and method for producing therapeutic formulation for central nervous system diseases
US12435308B2 (en) 2020-11-06 2025-10-07 Amniotics Ab Immunomodulation by amniotic fluid mesenchymal stem cells
CN112826920A (zh) * 2021-01-23 2021-05-25 中国人民解放军陆军军医大学 Id1/id3在诱导成纤维细胞重编程为施万细胞促进神经再生的应用
CN113652491A (zh) * 2021-02-02 2021-11-16 暨南大学 m6A RNA甲基化含量及其甲基化相关酶和结合蛋白在制备衰老检测试剂盒中的应用
TWI836572B (zh) * 2021-08-31 2024-03-21 約書亞健康事業股份有限公司 從疝氣囊分離純化間質幹細胞的方法及源自於疝氣囊的間質幹細胞用於組織修復的用途
CN114164216B (zh) * 2021-12-21 2023-08-25 北京航空航天大学 一种基因在促进骨形成中的应用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4038139A (en) * 1976-07-16 1977-07-26 G. D. Searle & Co., Limited Cell culture medium
US5486359A (en) * 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US5736396A (en) * 1995-01-24 1998-04-07 Case Western Reserve University Lineage-directed induction of human mesenchymal stem cell differentiation
JP3211941B2 (ja) 1996-12-26 2001-09-25 科学技術振興事業団 ヒト小型肝細胞の取得方法と、この細胞の初代培養および継代培養方法
US6335195B1 (en) * 1997-01-28 2002-01-01 Maret Corporation Method for promoting hematopoietic and mesenchymal cell proliferation and differentiation
US5968829A (en) 1997-09-05 1999-10-19 Cytotherapeutics, Inc. Human CNS neural stem cells
TR200401091T4 (tr) 1999-12-28 2004-06-21 Iso Tis N.V. Gelişim faktörleri ve L-glutamin içeren hücre kültürü besiyeri
KR100947577B1 (ko) * 2000-06-26 2010-03-15 엔씨 메디컬 리서치 가부시키가이샤 신경계 세포로 분화할 수 있는 세포를 포함하는 세포분획
JP2003052360A (ja) 2001-08-20 2003-02-25 Japan Science & Technology Corp 基底膜細胞外基質を用いた間葉系幹細胞の培養方法
EP1452586B1 (en) 2001-10-30 2012-05-30 Nc Medical Research Inc. Method of inducing differentiation of mesodermal stem cells into nervous system cells
JP2003235548A (ja) 2001-12-13 2003-08-26 Japan Science & Technology Corp ヒト細胞の培養用培地および培養方法
ES2198216B1 (es) * 2002-07-02 2005-04-16 Juan Carlos Instituto Cientifico Y Tecnologico De Navarra, S.A.(67%). Medio de cultivo de celulas madre-progenitoras autologas humanas y sus aplicaciones.
JPWO2004076652A1 (ja) * 2003-02-25 2006-06-08 学校法人東海大学 椎間板再生用の幹細胞用培地及び幹細胞を用いた椎間板の再生
US20070178591A1 (en) * 2004-06-25 2007-08-02 Renomedix Institute, Inc Internally administered therapeutic agents for diseases in central and peripheral nervous system comprising mesenchymal cells as an active ingredient
JP3706128B2 (ja) 2003-06-27 2005-10-12 株式会社レノメディクス研究所 治療用自己細胞の配送支援システム及びその方法
JPWO2005007176A1 (ja) 2003-06-27 2006-08-31 株式会社レノメディクス研究所 間葉系細胞を有効成分とする体内投与用脳神経疾患治療薬
US20060210544A1 (en) * 2003-06-27 2006-09-21 Renomedix Institute, Inc. Internally administered therapeutic agents for cranial nerve diseases comprising mesenchymal cells as an active ingredient
CN1590537A (zh) * 2003-09-02 2005-03-09 中国人民解放军第四军医大学口腔医学院 外胚间充质干细胞的分离和培养方法
JP4651282B2 (ja) 2004-01-21 2011-03-16 田辺三菱製薬株式会社 造血幹細胞及び造血前駆細胞の増幅方法
JP4597538B2 (ja) 2004-02-03 2010-12-15 独立行政法人産業技術総合研究所 神経幹細胞増殖助剤及びこれを含んだ神経幹細胞用培地
JP2006034118A (ja) * 2004-07-23 2006-02-09 Kaneka Corp 間葉系幹細胞の効率的保存または調製方法
JP2006055106A (ja) * 2004-08-23 2006-03-02 National Institute Of Advanced Industrial & Technology ヒト血清培地を用いるヒト骨髄由来間葉系幹細胞培養法
JP2006136281A (ja) * 2004-11-15 2006-06-01 Olympus Corp 培地および間葉系幹細胞の培養方法
JPWO2006054448A1 (ja) 2004-11-19 2008-05-29 株式会社ジェイ・エム・エス 細胞培養用ヒト血清
CN1699557A (zh) 2005-05-26 2005-11-23 南开大学 一种骨髓间充质干细胞的分离及培养方法
US20070047270A1 (en) 2005-09-01 2007-03-01 Creative Technology Ltd. Load detector for an AC-AC power supply
US20080199849A1 (en) * 2005-09-02 2008-08-21 Agency For Science, Technology And Research Method of Deriving Progenitor Cell Line
JP2007235436A (ja) 2006-02-28 2007-09-13 Sunx Ltd 電子回路及び光電センサ
JP5170967B2 (ja) 2006-03-06 2013-03-27 株式会社大一商会 遊技機
JP4719604B2 (ja) 2006-03-29 2011-07-06 エヌ・ティ・ティ アイティ株式会社 コマーシャル検出方法およびコマーシャル検出装置並びにコマーシャル検出プログラムが記録された記録媒体
JP4779775B2 (ja) 2006-04-03 2011-09-28 日産自動車株式会社 内燃機関の吸気制御装置
JP2007278049A (ja) 2006-04-07 2007-10-25 Voice Interface:Kk 凝固剤注入によるアスベスト封じ込めシステム
PT2194121T (pt) * 2007-09-11 2016-12-05 Univ Sapporo Medical Método de proliferação celular e agente farmacêutico para reparação e regeneração de tecidos

Also Published As

Publication number Publication date
CN101802174A (zh) 2010-08-11
KR20160005140A (ko) 2016-01-13
KR102087366B1 (ko) 2020-03-10
DK2194121T3 (en) 2016-12-12
US20100254953A1 (en) 2010-10-07
US20170266234A1 (en) 2017-09-21
ES2611021T3 (es) 2017-05-04
KR20170116219A (ko) 2017-10-18
JPWO2009034708A1 (ja) 2010-12-24
EP2194121A4 (en) 2012-03-07
CA2699236A1 (en) 2009-03-19
PT2194121T (pt) 2016-12-05
US10328102B2 (en) 2019-06-25
EP3117828A1 (en) 2017-01-18
US11426432B2 (en) 2022-08-30
PL2194121T3 (pl) 2017-02-28
US20190255118A1 (en) 2019-08-22
AU2008298816A1 (en) 2009-03-19
US9700582B2 (en) 2017-07-11
PT3117828T (pt) 2020-03-17
KR20100072240A (ko) 2010-06-30
WO2009034708A1 (ja) 2009-03-19
KR101614823B1 (ko) 2016-04-22
CN101802174B (zh) 2013-06-05
EP2194121B1 (en) 2016-10-26
ES2776408T3 (es) 2020-07-30
CA2699236C (en) 2017-02-28
EP2194121A1 (en) 2010-06-09
AU2008298816B2 (en) 2013-09-26
DK3117828T3 (da) 2020-03-09
JP4936341B2 (ja) 2012-05-23
EP3117828B1 (en) 2020-02-12

Similar Documents

Publication Publication Date Title
PL3117828T3 (pl) Sposób namnażania komórek i środek farmaceutyczny do naprawy i regeneracji tkanek
DK2078073T3 (da) Nyreafledte celler og fremgangsmåder til anvendelse deraf til vævsreparation og -regenerering
FI20085839A0 (fi) Menetelmiä ja välineitä pehmytkudosteknologiaan
DE602006001370D1 (de) Elektrochirurgische Zange mit langsam schließenden Versiegelungsplatten und Verfahren um Gebewe zu versiegeln
IL254144A0 (en) Methods for reprogramming cells and uses thereof
PT2055308T (pt) Medicamento para promover a regeneração funcional de tecido danificado
IT1396051B1 (it) Procedimento di minimizzazione in sito dei fanghi di depurazione dei reflui e di altri rifiuti.
EP2191526A4 (en) METHODS AND SYSTEMS FOR MANUFACTURING NANOWIL BATTERIES
HRP20160859T1 (hr) Modificirani proteini rsv f i postupci njihove upotrebe
EP2023811A4 (en) SURGICAL PATH CONTROL SYSTEM AND ASSOCIATED METHODS
IL199797A0 (en) Methods and devices for heart tissue repair
BRPI0807525A2 (pt) Dispositivo endo-cirúrgico e método
BRPI0814330A2 (pt) métodos e kits cirúrgicos
DK2491056T3 (da) Vhh til anvendelse i vævsreparation, organregenerering, organudskiftning og vævskonstruktion
EP2046122A4 (en) INHIBITORS OF HEM OXYGENASE AND METHODS OF THERAPEUTIC USE
DK2089047T3 (da) Sammensætninger og fremgangsmåder til beskyttelse og regenerering af hjerte-væv
IL210755A0 (en) Devices and methods for forming tracts in tissue
FI20065294L (fi) Menetelmä ja laitteisto akkukennojen hoitamiseksi
DK2313404T3 (da) Quinuclidin-carbonat-derivater og medicinsk sammensætning deraf
BRPI0822349A2 (pt) composições e métodos para tratar doenças lisossômicas
EP2019859A4 (en) ADULT FAMILY CELLS FROM FAT TISSUE FOR LIVER REGENERATION
BRPI1013509A2 (pt) método e composição para melhorar a absorção de agentes terapêuticos
EP2393787A4 (en) CADHERIN-11 INHIBITORS AND ASSOCIATED METHODS OF USE
BRPI0812517A2 (pt) Composições de célula derivada de tecido umbilical humano para o tratamento de incontinência
EP2114457A4 (en) COMPOSITION TO PROMOTE BONE REGENERATION AND RECONSTRUCTION